01541 IMMUNEONCO-B
- 14.700
- +0.380+2.65%
IMMUNEONCO-B News
宜明昂科-B：2023年報
Gelonghui Announcements Selected (Hong Kong Stock) | Xiaopeng Automobile-W (09868.HK) signs strategic cooperation framework agreement with Volkswagen Group on electronic and electrical architecture technology
[Today's Focus] Xiaopeng Motor-W (09868.HK) and Volkswagen Group sign a strategic cooperation framework agreement on electronic and electrical architecture technology Xiaopeng Motor-W (09868.HK) and Volkswagen Group jointly announced that Xiaopeng Motor and Volkswagen Group have signed a strategic cooperation framework agreement on electronic and electrical architecture (“electronic and electrical architecture”) technology. The industry-leading electronic and electrical architecture independently developed by Xiaopeng Motor is the core technology of its vertically integrated software and hardware technology. Thanks to this advanced electronic and electrical architecture, software such as intelligent driving assistance software and connected vehicle operating systems can be decoupled from the underlying hardware and vehicle platform,
Yiming Angko-B (01541.HK): IMM01 (tidapecip) was approved by the State Drug Administration for phase III clinical trial program
Gelonghui, April 17 | Yiming Angko-B (01541.HK) announced that in April 2024, the Group has obtained approval from the China National Drug Administration for recurrent or refractory (R/R) classic Hodgkin lymphoma (cL) that recurs or progresses after treatment with IMM01 (tidapacept) and tirelizumab in combination therapy with procedural cellular death protein 1 (PD-1) inhibitors. The Group's core product IMM01 (tidapecip) is an innovative targeting differentiation cluster 47 (CD47) molecule. This product is the first to enter China
Cansino Biotech (06185), the leading healthcare market, surged 15.12%, and Beijing, Guangzhou, and Zhuhai issued pharmaceutical innovation support policies
Jinwu Financial News | The healthcare sector led the market. Hang Seng Healthcare Index rose 1.93%. Among the constituent stocks, Cansino Biotech (06185) rose 15.12%, Junshi Biotech (01877) rose 11.9%, Genting Xinyao (01952) rose 7.8%, Yiming Angke (01541) rose 7.79%, Pharmaceuticals (02268) rose 5.98%, and Tiger Pharmaceuticals (03347) rose 5.8%. According to the news, the Beijing Municipal Medical Security Administration issued “On “Certain Measures to Support the High-Quality Development of Innovative Pharmaceuticals by 9 Departments Including the Beijing Municipal Medical Security Administration” (202
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases
Immuneonco Biopharmaceuticals' (HKG:1541) loss narrowed to 379.5 million yuan or 1.05 yuan per share, in 2023, from 402.9 million yuan, or 1.21 yuan per share, in 2022, according to a Tuesday filing w
Yiming Enko-B (01541.HK) reduced its annual net loss to 380 million yuan, continuing to rapidly advance the development of drug pipelines
On March 25, GLONGHUI | Yiming Angko-B (01541.HK) announced its annual results. The Group's loss during the year was reduced from RMB 402.9 million for the year ended December 31, 2022 to RMB 379.5 million for the year ended December 31, 2023. R&D expenditure increased 5.3% from RMB 277.3 million for the year ended 31 December 2022 to RMB 291.9 million for the year ended 31 December 2023, mainly due to (i) an increase of RMB 24 in clinical trial expenses due to the progress of clinical drug candidates
Yiming Onko-B (01541) will continue to support R&D in 2023
Yiming Angko-B (01541) announced its 2023 results, with revenue of about 386,000 yuan and an increase in R&D expenses by 5...
IMMUNEONCO-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Changes in Hong Kong stocks | Yiming Enko-B (01541) quickly rose by more than 20%. The company will hold a board meeting next Monday to consider and approve annual results
Yiming Enko-B (01541) quickly rose by more than 20%. As of press release, it rose 20.27% to HK$17.8, with a turnover of HK$3.31 million.
Yiming Enko-B (01541.HK) held a board meeting on March 25 to consider and approve the annual results
Glonghui, March 13 | Yiming Enko-B (01541.HK) announced that the company will hold a board meeting on March 25, 2024 (Monday) to consider and approve the results and publication of the company and its subsidiaries for the year ended 31 December 2023, and to consider recommending payment of a final dividend (if any).
IMMUNEONCO-B: DATE OF BOARD MEETING
Changes in Hong Kong stocks | Yiming Enko-B (01541) rebounded more than 8%, and the stock price fell to 40% in the past 7 trading days. The company confirmed that business operations remained normal
Yiming Enko-B (01541) has rebounded by more than 8%. The stock price has continued to fall recently, with a cumulative decline of more than 40% over the past 7 trading days. As of press release, it rose 8.19% to HK$15.58, with a turnover of HK$3.614,800.
Yiming Onko-B: Unusual share price fluctuations, business operations and clinical development remain normal
Yiming Angko-B (01541) issued an announcement. The board of directors of the company noticed unusual fluctuations in the company's share price recently. After making reasonable enquiries, the Board confirmed that, as of the date of this announcement, it was unaware of any reason for the share price fluctuation, or any information required to be disclosed to avoid a false market in the Company's securities, or any insider information required to be disclosed under Part XIVA of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong. As of the date of this announcement, the Board of Directors confirmed that the Group's business operations and clinical development have remained normal, and that there have been no significant adverse changes in the Group's business operations and financial situation
Yiming Onko-B (01541): Unusual stock price fluctuations, business operations and clinical development remain normal
Yiming Angko-B (01541) issued an announcement. The company's board of directors noticed an unusual trend in the company's share price recently...
Institutional Investors in ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) Must Be Dismayed After Prices Dropped by 26% Last Week
Key Insights Given the large stake in the stock by institutions, ImmuneOnco Biopharmaceuticals (Shanghai)'s stock price might be vulnerable to their trading decisions 52% of the business is held by
Immuneonco Biopharmaceuticals CFO Resigns
Immuneonco Biopharmaceuticals (Shanghai) (HKG:1541) Chief Financial Officer Song Ziyi resigned, effective Mar. 2, according to a Friday filing. Song, who is pursuing other business commitments, also c
Yiming Enko-B announced that Tian Wenzhi was appointed as authorized representative
Yiming Angko-B (01541) issued an announcement. Song Ziyi has proposed to resign as the company's executive director and chief financial officer, effective March 2, 2024 to spend more time on other commercial matters. Following the resignation of Ms. Song, he also ceased to act as an authorized representative of the company in accordance with section 3.05 of the Hong Kong Stock Exchange Limited securities listing rules. After considering the recommendations of the Board Nomination Committee, the Board of Directors decided to nominate Guan Mei as the company's executive director. The proposed appointment of Ms. Kwan will not be confirmed until the shareholders approve it in the form of an ordinary resolution at the recent annual general meeting of shareholders of the company. Chairman of the company, head
Yiming Angko-B (01541.HK) nominated Guan Mei as Executive Director
Gelonghui March 1 | Yiming Angko-B (01541.HK) announced that Song Ziyi has proposed to resign as the company's executive director and chief financial officer, effective March 2, 2024, to spend more time on other commercial matters. After considering the recommendations of the Board Nomination Committee, the Board of Directors decided to nominate Guan Mei as the company's executive director.
Yiming Enko-B (01541): Tian Wenzhi appointed as authorized representative
Yiming Angko-B (01541) issued an announcement. Song Ziyi has proposed the resignation of the company's executive director and chief financial officer since 2...
The cornerstone ban is about to be lifted. Can the broken Yiming Angko-B (01541) still rely on CD47 to support the valuation?
Once the listing ban period has passed, Yiming Encore needs to guarantee that the stock price is higher than HK$18.60 in order to give Cornerstone investors a satisfactory response.
Analysis
Price Target
No Data
